Annalisa Chiappella1, Maurizio Martelli2, Emanuele Angelucci3, Ercole Brusamolino4, Andrea Evangelista5, Angelo Michele Carella6, Caterina Stelitano7, Giuseppe Rossi8, Monica Balzarotti9, Francesco Merli10, Gianluca Gaidano11, Vincenzo Pavone12, Luigi Rigacci13, Francesco Zaja14, Alfonso D'Arco15, Nicola Cascavilla16, Eleonora Russo2, Alessia Castellino17, Manuel Gotti4, Angela Giovanna Congiu6, Maria Giuseppina Cabras3, Alessandra Tucci8, Claudio Agostinelli18, Giovannino Ciccone5, Stefano A Pileri19, Umberto Vitolo17. 1. Department of Haematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Turin, Italy. Electronic address: achiappella@cittadellasalute.to.it. 2. Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy. 3. Department of Haematology, Ospedale Armando Businco Cagliari, Haematology & Transplant Centre Wilma Deplano, Cagliari, Italy. 4. Departments of Haematology and Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. 5. Unit of Clinical Epidemiology, CPO, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Turin, Italy. 6. Department of Haematology, IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy. 7. Department of Haematology, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy. 8. Department of Haematology, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy. 9. Department of Haematology, Istituto Clinico Humanitas, Rozzano, Italy. 10. Department of Haematology, Arcispedale Santa Maria Nuova, IRCCS, Reggio Emilia, Italy. 11. Division of Haematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy. 12. Department of Haematology and Transplantation, Azienda Ospedaliera Cardinal Panico, Tricase, Italy. 13. Department of Haematology, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy. 14. Department of Haematology, Azienda Ospedaliero-Universitaria Santa Maria della Misericordia, Udine, Italy. 15. Department of Haematology, Presidio Ospedaliero Umberto I, Nocera Inferiore, Italy. 16. Department of Haematology, Hospital Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy. 17. Department of Haematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Turin, Italy. 18. Institute of Haematology L e A Seràgnoli, Università degli Studi di Bologna, Bologna, Italy. 19. Institute of Haematology L e A Seràgnoli, Università degli Studi di Bologna, Bologna, Italy; Haematopathology Unit, Istituto Europeo di Oncologia, Milan, Italy.
Abstract
BACKGROUND: The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated withR-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) is poor. The aim of this study was to investigate the possible benefit of intensification with high-dose chemotherapy and autologous stem-cell transplantation as part of first-line treatment in these patients. METHODS: We did a multicentre, open-label, randomised, controlled, phase 3 trial with a 2 × 2 factorial design to compare, at two different R-CHOP dose levels, a full course of rituximab-dose-dense chemotherapy (no transplantation group) versus an abbreviated course of rituximab-dose-dense chemotherapy followed by consolidation with R-MAD (rituximab plus high-dose cytarabine plus mitoxantrone plus dexamethasone) and high-dose BEAM chemotherapy (carmustine, etoposide, cytarabine, and melphalan) plus autologous stem-cell transplantation (transplantation group) in young patients (18-65 years) with untreated high-risk diffuse large B-cell lymphoma (aa-IPI score 2-3). At enrolment, patients were stratified according to aa-IPI score and randomly assigned (1:1:1:1) to receive R-CHOP (intravenous rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1·4 mg/m2 on day 1, plus oral prednisone 100 mg on days 1-5) delivered in a 14-day cycle (R-CHOP-14) for eight cycles; high-dose R-CHOP-14 (R-MegaCHOP-14; R-CHOP-14 except for cyclophosphamide 1200 mg/m2 and doxorubicin 70 mg/m2) for six cycles; R-CHOP-14 for four cycles followed by R-MAD (intravenous rituximab 375 mg/m2 on day 1 or 4 plus intravenous cytarabine 2000 mg/m2 and dexamethasone 4 mg/m2 every 12 h on days 1-3 plus intravenous mitoxantrone 8 mg/m2 on days 1-3) plus BEAM (intravenous carmustine 300 mg/m2 on day -7, intravenous cytarabine 200 mg/m2 twice a day on days -6 to -3, intravenous etoposide 100 mg/m2 twice a day on days -6 to -3, plus intravenous melphalan 140 mg/m2 on day -2) and autologous stem-cell transplantation (day 0); or R-MegaCHOP-14 for four cycles followed by R-MAD plus BEAM and autologous stem-cell transplantation. The primary endpoint was failure-free survival at 2 years in the intention-to-treat population. This study is registered with EudraCT (2005-002181-14; 2007-000275-42) and with ClinicalTrials.gov, number NCT00499018. FINDINGS:Between Jan 10, 2006, and Sept 8, 2010, 399 patients were randomly assigned to receive transplantation (n=199) or no transplantation (n=200); 203 patients were assigned toreceive R-CHOP-14 and 196 were assigned to receive R-MegaCHOP-14. With a median follow-up of 72 months (IQR 57-88), 2-year failure-free survival was 71% (95% CI 64-77) in the transplantation group versus 62% (95% CI 55-68) in the no transplantation group (hazard ratio [HR] 0·65 [95% CI 0·47-0·91]; stratified log-rank test p=0·012). No difference in 5-year overall survival was observed between these groups (78% [95% CI 71-83] versus 77% [71-83]; HR 0·98 [0·65-1·48]; stratified log-rank test p=0·91). Grade 3 or worse haematological adverse events were reported in 183 (92%) of 199 patients in the transplantation group versus 135 (68%) of 200 patients in the no transplantation group. Grade 3 or worse non-haematological adverse events were reported in 90 (45%) versus 31 (16%); the most common grade 3 or worse non-haematological adverse event was gastrointestinal (49 [25%] vs 19 [10%]). Treatment-related deaths occurred in 13 (3%) patients; eight in the transplantation group and five in the no transplantation group. INTERPRETATION:Abbreviated rituximab-dose-dense chemotherapy plus R-MAD plus BEAM and autologous stem-cell transplantation reduced the risk of treatment failure compared with full course rituximab-dose-dense chemotherapy in young patients with diffuse large B-cell lymphoma at high risk. However, these results might not be clinically meaningful, since this improvement did not reflect an improvement in overall survival. These results do not support further consideration of the use of intensification of R-CHOP as an upfront strategy in patients with diffuse large B-cell lymphoma with poor prognosis. FUNDING: Fondazione Italiana Linfomi.
RCT Entities:
BACKGROUND: The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) is poor. The aim of this study was to investigate the possible benefit of intensification with high-dose chemotherapy and autologous stem-cell transplantation as part of first-line treatment in these patients. METHODS: We did a multicentre, open-label, randomised, controlled, phase 3 trial with a 2 × 2 factorial design to compare, at two different R-CHOP dose levels, a full course of rituximab-dose-dense chemotherapy (no transplantation group) versus an abbreviated course of rituximab-dose-dense chemotherapy followed by consolidation with R-MAD (rituximab plus high-dose cytarabine plus mitoxantrone plus dexamethasone) and high-dose BEAM chemotherapy (carmustine, etoposide, cytarabine, and melphalan) plus autologous stem-cell transplantation (transplantation group) in young patients (18-65 years) with untreated high-risk diffuse large B-cell lymphoma (aa-IPI score 2-3). At enrolment, patients were stratified according to aa-IPI score and randomly assigned (1:1:1:1) to receive R-CHOP (intravenous rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1·4 mg/m2 on day 1, plus oral prednisone 100 mg on days 1-5) delivered in a 14-day cycle (R-CHOP-14) for eight cycles; high-dose R-CHOP-14 (R-MegaCHOP-14; R-CHOP-14 except for cyclophosphamide 1200 mg/m2 and doxorubicin 70 mg/m2) for six cycles; R-CHOP-14 for four cycles followed by R-MAD (intravenous rituximab 375 mg/m2 on day 1 or 4 plus intravenous cytarabine 2000 mg/m2 and dexamethasone 4 mg/m2 every 12 h on days 1-3 plus intravenous mitoxantrone 8 mg/m2 on days 1-3) plus BEAM (intravenous carmustine 300 mg/m2 on day -7, intravenous cytarabine 200 mg/m2 twice a day on days -6 to -3, intravenous etoposide 100 mg/m2 twice a day on days -6 to -3, plus intravenous melphalan 140 mg/m2 on day -2) and autologous stem-cell transplantation (day 0); or R-MegaCHOP-14 for four cycles followed by R-MAD plus BEAM and autologous stem-cell transplantation. The primary endpoint was failure-free survival at 2 years in the intention-to-treat population. This study is registered with EudraCT (2005-002181-14; 2007-000275-42) and with ClinicalTrials.gov, number NCT00499018. FINDINGS: Between Jan 10, 2006, and Sept 8, 2010, 399 patients were randomly assigned to receive transplantation (n=199) or no transplantation (n=200); 203 patients were assigned to receive R-CHOP-14 and 196 were assigned to receive R-MegaCHOP-14. With a median follow-up of 72 months (IQR 57-88), 2-year failure-free survival was 71% (95% CI 64-77) in the transplantation group versus 62% (95% CI 55-68) in the no transplantation group (hazard ratio [HR] 0·65 [95% CI 0·47-0·91]; stratified log-rank test p=0·012). No difference in 5-year overall survival was observed between these groups (78% [95% CI 71-83] versus 77% [71-83]; HR 0·98 [0·65-1·48]; stratified log-rank test p=0·91). Grade 3 or worse haematological adverse events were reported in 183 (92%) of 199 patients in the transplantation group versus 135 (68%) of 200 patients in the no transplantation group. Grade 3 or worse non-haematological adverse events were reported in 90 (45%) versus 31 (16%); the most common grade 3 or worse non-haematological adverse event was gastrointestinal (49 [25%] vs 19 [10%]). Treatment-related deaths occurred in 13 (3%) patients; eight in the transplantation group and five in the no transplantation group. INTERPRETATION: Abbreviated rituximab-dose-dense chemotherapy plus R-MAD plus BEAM and autologous stem-cell transplantation reduced the risk of treatment failure compared with full course rituximab-dose-dense chemotherapy in young patients with diffuse large B-cell lymphoma at high risk. However, these results might not be clinically meaningful, since this improvement did not reflect an improvement in overall survival. These results do not support further consideration of the use of intensification of R-CHOP as an upfront strategy in patients with diffuse large B-cell lymphoma with poor prognosis. FUNDING: Fondazione Italiana Linfomi.
Authors: David M Kurtz; Mohammad S Esfahani; Florian Scherer; Joanne Soo; Michael C Jin; Chih Long Liu; Aaron M Newman; Ulrich Dührsen; Andreas Hüttmann; Olivier Casasnovas; Jason R Westin; Matthais Ritgen; Sebastian Böttcher; Anton W Langerak; Mark Roschewski; Wyndham H Wilson; Gianluca Gaidano; Davide Rossi; Jasmin Bahlo; Michael Hallek; Robert Tibshirani; Maximilian Diehn; Ash A Alizadeh Journal: Cell Date: 2019-07-04 Impact factor: 41.582
Authors: David M Kurtz; Florian Scherer; Michael C Jin; Joanne Soo; Alexander F M Craig; Mohammad Shahrokh Esfahani; Jacob J Chabon; Henning Stehr; Chih Long Liu; Robert Tibshirani; Lauren S Maeda; Neel K Gupta; Michael S Khodadoust; Ranjana H Advani; Ronald Levy; Aaron M Newman; Ulrich Dührsen; Andreas Hüttmann; Michel Meignan; René-Olivier Casasnovas; Jason R Westin; Mark Roschewski; Wyndham H Wilson; Gianluca Gaidano; Davide Rossi; Maximilian Diehn; Ash A Alizadeh Journal: J Clin Oncol Date: 2018-08-20 Impact factor: 44.544
Authors: A Castellino; A Chiappella; B R LaPlant; L D Pederson; G Gaidano; W R Macon; G Inghirami; C B Reeder; A Tucci; R L King; A Congiu; J M Foran; V Pavone; C E Rivera; M Spina; S M Ansell; F Cavallo; A L Molinari; Giovannino Ciccone; T M Habermann; T E Witzig; U Vitolo; G S Nowakowski Journal: Blood Cancer J Date: 2018-11-08 Impact factor: 11.037